NeOnc board sees resignation of director, election of CEO's niece as replacement
Ming-Fu Chiang stepped down from NeOnc Technologies Holdings' board on June 27, 2026, and Nasim Shomali, a relative of the company's CEO, was elected to the seat days later.
NeOnc Technologies Holdings, Inc. disclosed in a Form 8-K that on June 27, 2026, Ming-Fu (Alan) Chiang, M.D., Ph.D., MBA, a Class II director, notified the company of his resignation as a member of the Board of Directors, effective immediately.1 Along with the board departure, Dr. Chiang also resigned from the company's Scientific Advisory Board.1 The company stated that the resignation did not stem from any disagreement with the company over its operations, policies, or practices.1
On July 1, 2026, the board elected Nasim Shomali as a director, effective immediately, to serve as a Class II director until the company's 2027 annual meeting of stockholders.1
According to the filing, Shomali worked as a Strategy Executive at Accenture from April 2013 to April 2026.1 In that role, the filing describes her as having advised large corporations on strategic planning and organizational change, including work on product development, market expansion, and efficiency initiatives, and having managed and expanded Accenture's U.S. Software, Platform, and Technology sustainability portfolio.1
Her academic background includes an M.B.A. with a concentration in finance from the UCLA Anderson School of Management.1 She also holds two undergraduate degrees, one in bioengineering and one in mathematics, from the University of Washington, and completed a leadership program focused on sustainability at Yale's School of Management, per the filing.
The company noted that there was no arrangement or understanding between Shomali and any other person related to her selection as director.1 However, the filing discloses that Shomali is the niece of Amir Heshmatpour, the company's President, Chief Executive Officer and Executive Chairman.1
Written by readthrough’s AI from the linked primary sources and fact-checked against them automatically before publishing. Not investment advice.